Nathan D. Jorgensen
Known title: Chief Financial OfficerCIK: 0001842523
Associated companies
Transaction History
| VYGR | ▼ Sell | Open Market | 4,668 | $18K | 2/24/2026 | View on chart |
| VYGR | ▲ Buy | Grant | 32,250 | $0 | 2/6/2026 | View on chart |
| VYGR | ▼ Sell | Open Market | 7,666 | $37K | 10/3/2025 | View on chart |
| VYGR | ▲ Buy | Grant | 51,500 | $0 | 2/21/2025 | View on chart |
| VYGR | ▲ Buy | Grant | 80,000 | $0 | 10/1/2024 | View on chart |
| VOR | ▼ Sell | Tax Withholding | 834 | $1K | 5/6/2024 | View on chart |
| VOR | ▼ Sell | Tax Withholding | 917 | $2K | 5/1/2024 | View on chart |
| VOR | ▼ Sell | Tax Withholding | 6,310 | $14K | 3/1/2024 | View on chart |
| VOR | ▼ Sell | Tax Withholding | 985 | $2K | 2/6/2024 | View on chart |
| VOR | ▲ Buy | Grant | 50,000 | $0 | 1/29/2024 | View on chart |
| VOR | ▼ Sell | Tax Withholding | 834 | $2K | 11/6/2023 | View on chart |
| VOR | ▼ Sell | Tax Withholding | 6,310 | $17K | 9/1/2023 | View on chart |
| VOR | ▼ Sell | Tax Withholding | 834 | $2K | 8/7/2023 | View on chart |
| VOR | ▼ Sell | Tax Withholding | 834 | $3K | 5/8/2023 | View on chart |
| VOR | ▼ Sell | Tax Withholding | 6,310 | $35K | 3/1/2023 | View on chart |
| VOR | ▲ Buy | Grant | 45,500 | $0 | 2/6/2023 | View on chart |
| VOR | ▲ Buy | Grant | 86,000 | $0 | 9/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Vor Biopharma Phase 3 data draws valuation focus
Recent analysis suggests Vor Biopharma may be undervalued as attention shifts to its Phase 3 data for generalized myasthenia gravis. This clinical milestone is central to the stock's current narrative, with analysts maintaining a wide range of price targets. The company's low trailing P/E ratio provides additional context for its current valuation relative to its 52-week trading range.
Vor Biopharma Phase 3 data draws valuation focus. Recent analysis suggests Vor Biopharma may be undervalued as attention shifts to its Phase 3 data for generalized myasthenia gravis. This clinical milestone is central to the stock's current narrative, with analysts maintaining a wide range of price targets. The company's low trailing P/E ratio provides additional context for its current valuation relative to its 52-week trading range.